This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Tolerability of combination therapy

In the CombAT study, dutasteride co-prescribed with tamsulosin has a well documented safety profile 1

Treatment-related adverse events occurring in ≥1% of subjects in any treatment group. 1

 

References:

  1. Roehrborn CG, et al. Eur Urol 2010;57:123–131.

Trade marks are owned by or licensed to the GSK group of companies.
©2021 GSK group of companies or its licensor.